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Abstract
Xenotransplantation using genetically modified pig organs could solve the donor organ shortage 
problem. Two inactivated genes that make humans unique from pigs are GGTA1 and CMAH, the 
products of which produce the carbohydrate epitopes, aGal and Neu5Gc that attract preformed 
human antibody. When the GGTA1 and CMAH genes were deleted in pigs human antibody 
binding was reduced in preliminary analysis. We analyzed the binding of human IgM and IgG 
from 121 healthy human serum samples for binding to GGTA1 KO and GGTA1/CMAH KO 
peripheral blood mononuclear cells (PBMC). We analyzed a sub population for reactivity towards 
genetically modified pig PBMC as compared to chimpanzee and human PBMC. Deletion of the 
GGTA1 and CMAH genes in pigs improved the crossmatch results beyond those observed with 
chimpanzees. Sorting the 121 human samples tested against the GGTA1/CMAH KO pig PBMC 
did not reveal a distinguishing feature such as blood group, age or gender. Modification of genes 
to make pig carbohydrates more similar to humans has improved the cross match with human 
serum significantly.
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Solid organ transplantation has developed into a field where patients’ lives are transformed 
from the brink of death to near normal. Improvements have been made in nearly all aspects 
of the field except one, the availability of donor organs. Xenotransplantation could solve the 
organ shortage problem, but has been limited because of the antibody barrier posed by 
xenoantigens present on the surface of all pig organs (1, 2).
In 1964 Reemtsma and Starzl published a series of non-human primate to human renal 
xenotransplants. Reemtsma used chimpanzee kidneys in six patients who survived 23 days 
to 9 months post-transplant (3). Starzl transplanted baboon kidneys into six patients who 
survived 10–60 days post-transplant (4). Immunosuppression in both series consisted of 
azathioprine, corticosteroids, and mitomycin C. Since both series were performed prior to 
the understanding that antibodies were responsible for hyperacute rejection, there were no 
detailed anti-donor antibody studies available (5).
Despite the advances in immunosuppression, clinical xenotransplantion did not progress, 
and the use of primates as donors fell out of favor. The use of pigs as organ donors became 
the focus of xenotransplantation, because pigs are plentiful, physiologically similar to 
humans, and less likely than primates to transmit zoonotic viruses (6). Hyperacute rejection 
was the survival-limiting barrier of pig-to-human xenografts, caused by preexisting 
xenoreactive antibodies and complement activation within the graft (7). Galactose α-1,3 
galactose (aGal) was identified as a major xenoantigen to which xenoreactive antibodies 
bound and fixed complement (8). The development of somatic cell nuclear transfer (SCNT) 
and genetic engineering made it possible to create galactosyltransferase knockout (GGTA1 
KO) pigs, whose organs were not hyperacutely rejected when transplanted into 
immunosuppressed baboons (9). Tolerogenic immunosuppressive protocols resulted in 
longer survival, but preformed and de novo xenoreactive antibodies remained a barrier to 
further xenograft survival (9, 10).
The expression of another carbohydrate xenoantigen N-glycolylneuraminic acid (Neu5Gc) 
has been eliminated in addition to aGal. Neu5Gc is present in pigs, but not in humans 
because like the GGTA1 gene, the CMAH gene was inactivated during the course of 
evolution (11–14). Our initial characterization of the aGal/Neu5Gc deficient pig has 
indicated that Neu5Gc is a significant xenoantigen present in all people we have tested thus 
far (14). Neu5Gc is present in all primates, and as a result the non-human primate is not a 
suitable model with which to test these new pig organs.
The work described in this report evaluates three issues regarding the GGTA1/CMAH KO 
pig; 1) the proportion of people for whom the GGTA1/CMAH KO has an improved 
crossmatch compared to the GGTA1 KO pig, 2) a comparison of the degree of discordance 
of the GGTA1/CMAH KO pig, GGTA1 KO pig and chimpanzees with regards to 
xenoreactive antibody levels present in human serum, and 3) whether there are patients who 
have lower or higher levels of remaining xenoreactive antibodies with regards to; blood 
type, age or gender.
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Serum antibody binding to GGTA1-KO and double-KO PBMCs (Flow Crossmatch)
Blood samples were collected from healthy humans or cloned genetically modified pigs 
(blood type O) using Institutional Review Board and Institutional Animal Care and Use 
Committee approved protocols (IRB#1110007111 and IACUC#10447). The 121 healthy 
human serum samples were collected from an FDA registered center using protocols 
approved by the American Association of Blood Banks (Valley Biomedical, Winchester, 
VA and Sanguine Biosciences Inc., Valencia, CA). Blood from 3 chimpanzees was obtained 
from the Southwest National Primate Research Center (Texas Biomedical Research 
Institute, San Antonio, TX)). Blood from cloned GGTA1/CMAH knockout pigs (type O), 
human (type A), and chimpanzees (two blood type A and one undetermined) corresponding 
to Figure 2 were separated using Ficoll-Paque Plus to collect PBMCs. GGTA1 KO, 
GGTA1/CMAH KO, chimpanzee and human PBMC were incubated with 25% heat 
inactivated serum from 5 human subjects: human 1 (type O), human 2 (type A), human 3 
(type A), human 4 (type O), human 5 (type O). PBMC were stained with DyLight 488-
conjugated Donkey anti-Human IgM or, DyLight 488 Goat anti-Human IgG (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA). Flow cytometry was performed using 
an Accuri C6 flow cytometer (Accuri, Ann Arbor, MI, USA). Antibody binding data to all 
types of PBMC within each experiment were collected at the same time. Human serum 
antibody binding was analyzed using FlowJo version 8.8.7 (Treestar Inc. Ashland, OR). The 
forward and side scatter gate excluded only dead cells and debris. Histograms of the 
fluorescent channel were used for determination of MFI and overlay. Flow cytometric 
results were reported as averages of the Median FI values where P values were determined 
by unpaired two-tailed T test shown for human IgM or IgG binding to GGTA1/CMAH KO 
PBMC (Figure 3).
Results
Impact of CMAH deletion on human crossmatch with GGTA1 KO PBMC
Cells from the GGTA1/CMAH KO pig bound less human antibody than a GGTA1 KO pig 
when tested against a small population of human sera, yet showed some variability (14). To 
more clearly define the benefit of the GGTA1/CMAH KO pig cells among a larger human 
population we tested 121 human serum samples for IgM and IgG binding to genetically 
modified pig PBMC. Human IgM and IgG binding to GGTA1 KO and GGTA1/CMAH KO 
PBMC analyzed by scatter plot (Figure 1) indicated that mutating the CMAH gene in 
addition to GGTA1 reduced antibody binding for 117 of the 121 individual tested (Figure 
1shown below the trend line). Pearson correlation analysis was calculated for IgM and IgG 
binding to GGTA1 KO and GGTA1/CMAH KO PBMC (r=0.157, 95% CI −0.0225 to 0.326 
and r=0.257, 95% CI 0.081 to 0.416, respectively) suggested a non-linear relationship where 
−1 is a perfect negative linear, 0 is non-linear and 1 is a perfect linear relationship.
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Crossmatch of GGTA1/CMAH pig with human serum compares favorably to the 
chimpanzee
Chimpanzee renal xenografts were rejected less vigorously than baboon kidneys (3, 4). We 
compared IgM and IgG binding from 5 human serum samples to PBMCs from 3 GGTA1/
CMAH pigs, 3 chimpanzees and 3 humans to evaluate whether we had created a concordant 
crossmatch pig. In 4 of the 5 human serum samples the GGTA1/CMAH KO pig PBMC 
bound less IgM and IgG than chimpanzee PBMC (Figure 2). The similarity of replicates 
suggests that differences between A and O blood groups did not influence human antibody 
binding. The degree of concordance or discordance was determined by comparison to the 
human antibody binding of human PBMC.
Applicability of CMAH benefit to segments of the human population
We evaluated whether human reactivity to the GGTA1/CMAH KO pigs was broadly 
applicable across blood types A (n=38), AB (n=22), B (n=30), O (n=31), age defined as old 
(n=59): 50–65 years or young (n=62): 18–30 years and gender: female (n=57) and male 
(n=64) (Figure 3). There were small but significant differences in IgG binding between 
young and old (P=0.001) and IgG binding to the O blood group as compared to A 
(P<0.001), AB (P<0.001) and B (P=0.008). Three individuals from the blood group O 
population had 10–20 times the antibody binding of the other human samples tested. When 
these 3 individuals were excluded, there was no difference in human reactivity to GGTA1/
CMAH KO PBMC based on blood group. Despite these small variations, the majority of 
individuals bound similar amounts of IgG and IgM. When Human IgG binding was 
compared between blood groups A and AB (P=0.932), A and B (P=0.892) or AB and B 
(P=0.06) no significant differences were found. Human IgM binding to all blood groups was 
not significantly different (A and O P=0.056, AB and O P=0.147, B and O P=0.075, A and 
AB P=0.966, A and B P=0.741, and AB and B P=0.76). There was no difference in IgG or 
IgM binding to male or female (P=0.172 and P=0.46, respectively). There was no difference 
in human IgM binding to the young or old (P=0.919).
Discussion
Despite tremendous improvements in solid organ transplantation in the past 40 years, 
xenotransplantation has remained limited to the experimental realm largely because of the 
risk of antibody-mediated rejection (AMR). The creation of the GGTA1 KO pig in 2002 was 
a major advance for xenotransplantation, but AMR remained the cause of graft failure in 
primate models (9, 15, 16). New pigs with reduced xenoantigenicity were not created 
because of the difficulty and expense associated with the creation of knockout pigs. The 
development of nuclease based genome editing made it possible to knockout more than one 
gene at a time in five months (14, 17, 18). We used ZFN technology to create the GGTA1/
CMAH KO pig, removing aGal and Neu5Gc from the surface of the pig cells (14). To 
evaluate the changes in immunoreactivity of the genetically modified pigs we used the 
clinical crossmatch test where donor PBMC bound by recipient serum antibodies is an 
predictor of graft success. Our data show that the crossmatch with the GGTA1/CMAH KO 
pig is an improvement when compared to the GGTA1 KO pig for nearly all patients tested. 
Our previous characterization of these genetically modified pigs suggested that the heart, 
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kidney and liver reflect the same loss of aGal and Neu5Gc as measured on PBMC (14). 
Therefore the crossmatch analysis is likely a good indicator of the changes in recipient 
immunoreactivity to the donor organ. It is possible, however, that new carbohydrate 
structures or organ specific glycosylations may become apparent xenoantigens as we reduce 
overall antibody binding.
Reemstma’s chimpanzee and Starzl’s baboon xenograft experiences showed that the non-
human primate donor kidney could be used without the threat of hyperacute rejection (19, 
20). Their clinical series were performed prior to the discovery that antibodies were 
responsible for aggressive forms of transplant rejection, and so their clinical series did not 
include detailed antibody data in the form of crossmatch analysis (5). Calne suggested that 
the first step in moving toward pig-to-human xenotransplantation was to convert the 
rejection reaction from discordant to concordant (5). Our crossmatch data show that humans 
in 4 of the 5 cases tested, have less antibody binding to GGTA1/CMAH KO pig than 
chimpanzee PBMCs. The data suggests that the GGTA1/CMAH KO pig and the 
chimpanzee are similar in terms of their discordance. This finding is significant in light of 
improvements in the diagnosis and management of sensitized patients on the waitlist. It may 
now make sense to re-evaluate IVIG for its ability to improve the crossmatch of human 
serum with the new GGTA1/CMAH KO pig. If IVIG or plasmapheresis can remove the 
remaining xenoantibodies in human serum, it is possible that a clinically used 
desensitization protocol and modern immunosuppression could pave the way for a clinical 
trial of pig-to-human renal xenografts (21). Baboons have a functional CMAH enzyme and 
express Neu5Gc. Baboon serum crossmatches with GGTA1/CMAH KO PBMCs is 
significantly worse than for GGTA1 KO PBMCs (data not shown), making it unlikely that 
these new pigs can be tested in a primate model. Thrombotic microangiopathy is the final 
common pathway for GGTA1 KO xenograft failure in baboons, raising the question of 
whether immunologic injury, or species thromboregulatory incompatibility is the next 
barrier to moving forward with clinical xenotransplantation (22). McGregor’s group showed 
increased immunosuppression, and not anticoagulation, improved heterotopic GGTA1 KO 
pig heart survival in baboons (23). Their work suggests that there is more to be gained from 
the continuing to eliminate xenoantigens in pigs.
Gene editing technology is improving at an incredible rate, and with the advent of the new 
Cas9 guide RNA technology, making new modified pigs has become simpler, faster, and 
less expensive than ever (24). Taking advantage of these advances could allow evaluation of 
other identified xenoantigens for improvement in the human serum crossmatch through 
additional genetic modifications in pigs. The iGb3 synthase adds aGal to glycolipids, and 
studies with GGTA1 KO fibroblasts showed that there is still gal present on these cells at 1–
2% of wild type levels (25). Studies in GGTA1 KO pigs have failed to show the presence of 
gal in organs, but studies in GGTA1 KO mice have shown that gal is still present despite the 
GGTA1 deletion (26–28). Creation of an iGb3S KO pig is the simplest way to definitively 
evaluate glycolipid bound galα(1,3)gal as a xenoantigen. We are currently evaluating 
GGTA1/iGb3S and GGTA1/iGb3S/CMAH KO pigs in our lab.
Our data also suggests that the crossmatch benefit of the CMAH deletion is widespread in 
the human population and is not limited to a particular blood type, age or gender. People 
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with blood type O did have increased antibody binding to the GGTA1/CMAH KO pigs 
when compared to people of blood groups A, B, and AB. The increased antibody binding in 
blood group individuals was the result of a small fraction of outliers, and while statistically 
significant, for most individuals their antibody binding was not significantly different from 
those on the other blood groups.
In summary the creation of the GGTA1/CMAH KO pig is an improvement over the GGTA1 
KO pig as far as reducing the antibody barrier to xenotransplantation is concerned. The 
GGTA1/CMAH KO pig was similar to the chimpanzee with regards to degree of 
discordance. Testing with desensitization protocols will determine whether the remaining 
xenoantibody can be managed with IVIG or plasmapheresis to facilitate clinical application 
of xenotransplantation. This work also highlights the fact that further reduction in the 
xenoantibody barrier may be achieved through the deletion of additional xenoantigens in 
donor pigs.
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ABBREVIATIONS
aGal galactose alpha-1,3 galactose
neu5Gc N-glycolyl neuraminic acid
neu5Ac N-acetyl neuraminic acid
CMAH cytidine monophosphate-N-acetylneuraminic acid hydroxylase
PBMCs peripheral blood mononuclear cells
HBSS Hank’s balanced salt solution
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Scatter plot of human IgM or IgG binding to either PBMC from GGTA1 KO (x-axis) and 
GGTA1/CMAH KO (y-axis) pigs. Values falling below the trend line indicates less antibody 
binding to the GGTA1/CMAH KO PBMC than to the GGTA1 KO PBMC.
Burlak et al. Page 9










Comparison of human antibody binding to human, porcine, or chimpanzee cells. PBMC 
isolated from humans, chimpanzees, and GGTA1/CMAH KO pigs incubated with 25% 
serum collected from five humans. Levels of IgM or IgG binding were detected using 
fluorescently labeled anti-human IgM or IgG antibodies followed by flow cytometric 
analysis. Histogram profiles of human IgM and IgG antibody binding are shown for 3 
humans (filled gray), 3 chimpanzees (black) and 3 GGTA1/CMAH KO pigs (red). 
Histogram profiles of PBMC incubated with fluorescently labeled anti-human IgM or IgG 
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antibodies in the absence of human serum are shown to indicate background fluorescence 
(2° only).
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Human IgM or IgG binding to GGTA1/CMAH KO PBMC sorted by blood types A (n=38), 
AB (n=22), B (n=30), O (n=31), age defined as young (n=62): 18–30 years or old (n=59): 
50–65 years, and gender: female (n=57) and male (n=64). Box and whisker plots are shown 
with the maximum and minimum values. Statistical significance was determined by 
unpaired two-tailed T test and indicated with an asterisk (*).
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